{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T19:48:16Z","timestamp":1781552896118,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Usona Institute Scholarship"},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["T32DA007250"],"award-info":[{"award-number":["T32DA007250"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR000038"],"award-info":[{"award-number":["UL1 TR000038"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013057","name":"Heffter Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Riverstyx Foundation William Linton Betsy Gordon Foundation McCormick Family Fetzer Institute George Goldsmith Ekaterina Malievskaia"},{"name":"RiverStyx Foundation NYU Clinical and Translational Science Institute Carey and Claudia Turnbull William Linton Robert Barnhart Arthur Altschul Kelly Fitzsimmons George Goldsmith Ekaterina Malievskaia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Mental Health"],"DOI":"10.1038\/s44220-024-00331-0","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T10:02:19Z","timestamp":1728295339000},"page":"1408-1414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer"],"prefix":"10.1038","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7608-5723","authenticated-orcid":false,"given":"Petros D.","family":"Petridis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Grinband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Agin-Liebes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor J.","family":"Kinslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Zeifman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4530-3470","authenticated-orcid":false,"given":"Michael P.","family":"Bogenschutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland R.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"331_CR1","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1001\/jama.1983.03330300035030","volume":"249","author":"LR Derogatis","year":"1983","unstructured":"Derogatis, L. R. et al. The prevalence of psychiatric disorders among cancer patients. JAMA 249, 751\u2013757 (1983).","journal-title":"JAMA"},{"key":"331_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/1099-1611(200101\/02)10:1<19::AID-PON501>3.0.CO;2-6","volume":"10","author":"J Zabora","year":"2001","unstructured":"Zabora, J., BrintzenhofeSzoc, K., Curbow, B., Hooker, C. & Piantadosi, S. The prevalence of psychological distress by cancer site. Psychooncology 10, 19\u201328 (2001).","journal-title":"Psychooncology"},{"key":"331_CR3","doi-asserted-by":"publisher","first-page":"591771","DOI":"10.3389\/fpsyg.2020.591771","volume":"11","author":"L Peters","year":"2020","unstructured":"Peters, L., Brederecke, J., Franzke, A., de Zwaan, M. & Zimmermann, T. Psychological distress in a sample of inpatients with mixed cancer\u2014a cross-sectional study of routine clinical data. Front Psychol 11, 591771 (2020).","journal-title":"Front Psychol"},{"key":"331_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1470-2045(11)70002-X","volume":"12","author":"AJ Mitchell","year":"2011","unstructured":"Mitchell, A. J. et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 12, 160\u2013174 (2011).","journal-title":"Lancet Oncol."},{"key":"331_CR5","doi-asserted-by":"publisher","first-page":"k1415","DOI":"10.1136\/bmj.k1415","volume":"361","author":"A Pitman","year":"2018","unstructured":"Pitman, A., Suleman, S., Hyde, N. & Hodgkiss, A. Depression and anxiety in patients with cancer. Br. Med. J. 361, k1415 (2018).","journal-title":"Br. Med. J."},{"key":"331_CR6","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1200\/JCO.2013.52.4611","volume":"32","author":"BL Andersen","year":"2014","unstructured":"Andersen, B. L. et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J. Clin. Oncol. 32, 1605\u20131619 (2014).","journal-title":"J. Clin. Oncol."},{"key":"331_CR7","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1001\/jama.1979.03300140020016","volume":"242","author":"LR Derogatis","year":"1979","unstructured":"Derogatis, L. R., Abeloff, M. D. & Melisaratos, N. Psychological coping mechanisms and survival time in metastatic breast cancer. JAMA 242, 1504\u20131508 (1979).","journal-title":"JAMA"},{"key":"331_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/pon.5594","volume":"30","author":"L Grassi","year":"2021","unstructured":"Grassi, L. et al. Hostility in cancer patients as an underexplored facet of distress. Psychooncology 30, 493\u2013503 (2021).","journal-title":"Psychooncology"},{"key":"331_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3109\/09540261.2012.731384","volume":"25","author":"L Grassi","year":"2013","unstructured":"Grassi, L., Caruso, R. & Nanni, M. G. Somatization and somatic symptom presentation in cancer: a neglected area. Int. Rev. Psychiatry 25, 41\u201351 (2013).","journal-title":"Int. Rev. Psychiatry"},{"key":"331_CR10","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.23.00293","volume":"41","author":"BL Andersen","year":"2023","unstructured":"Andersen, B. L. et al. Management of anxiety and depression in adult survivors of cancer: ASCO guideline update. J. Clin. Oncol. 41, 3426\u20133453 (2023).","journal-title":"J. Clin. Oncol."},{"key":"331_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-25068-7","volume":"12","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Cognitive behavioral therapy for anxiety and depression in cancer survivors: a meta-analysis. Sci. Rep. 12, 21466 (2022).","journal-title":"Sci. Rep."},{"key":"331_CR12","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1037\/0022-006X.54.5.608","volume":"54","author":"SE Taylor","year":"1986","unstructured":"Taylor, S. E., Falke, R. L., Shoptaw, S. J. & Lichtman, R. R. Social support, support groups, and the cancer patient. J. Consult. Clin. Psychol. 54, 608\u2013615 (1986).","journal-title":"J. Consult. Clin. Psychol."},{"key":"331_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/1097-0142(19860101)57:1<183::AID-CNCR2820570135>3.0.CO;2-3","volume":"57","author":"EN Cain","year":"1986","unstructured":"Cain, E. N., Kohorn, E. I., Quinlan, D. M., Latimer, K. & Schwartz, P. E. Psychosocial benefits of a cancer support group. Cancer 57, 183\u2013189 (1986).","journal-title":"Cancer"},{"key":"331_CR14","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s11764-019-00811-8","volume":"13","author":"JM Salsman","year":"2019","unstructured":"Salsman, J. M. et al. Psychosocial interventions for cancer survivors: a meta-analysis of effects on positive affect. J. Cancer Surviv. 13, 943\u2013955 (2019).","journal-title":"J. Cancer Surviv."},{"key":"331_CR15","first-page":"CD011006","volume":"4","author":"G Ostuzzi","year":"2018","unstructured":"Ostuzzi, G., Matcham, F., Dauchy, S., Barbui, C. & Hotopf, M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst. Rev. 4, CD011006 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"331_CR16","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/cncr.22980","volume":"110","author":"M Miovic","year":"2007","unstructured":"Miovic, M. & Block, S. Psychiatric disorders in advanced cancer. Cancer 110, 1665\u20131676 (2007).","journal-title":"Cancer"},{"key":"331_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2010.07.034","volume":"131","author":"CG Ng","year":"2011","unstructured":"Ng, C. G., Boks, M. P., Zainal, N. Z. & de Wit, N. J. The prevalence and pharmacotherapy of depression in cancer patients. J. Affect. Disord. 131, 1\u20137 (2011).","journal-title":"J. Affect. Disord."},{"key":"331_CR18","doi-asserted-by":"publisher","first-page":"100428","DOI":"10.1016\/j.ijchp.2023.100428","volume":"24","author":"L Azari","year":"2024","unstructured":"Azari, L. et al. The efficacy and safety of ketamine for depression in patients with cancer: a systematic review. Int. J. Clin. Health Psychol. 24, 100428 (2024).","journal-title":"Int. J. Clin. Health Psychol."},{"key":"331_CR19","doi-asserted-by":"publisher","first-page":"599721","DOI":"10.3389\/fphar.2020.599721","volume":"11","author":"C Culp","year":"2020","unstructured":"Culp, C., Kim, H. K. & Abdi, S. Ketamine use for cancer and chronic pain management. Front. Pharmacol. 11, 599721 (2020).","journal-title":"Front. Pharmacol."},{"key":"331_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-019-0499-1","volume":"19","author":"E Falk","year":"2020","unstructured":"Falk, E. et al. A rapid positive influence of S-ketamine on the anxiety of patients in palliative care: a retrospective pilot study. BMC Palliative Care 19, 1 (2020).","journal-title":"BMC Palliative Care"},{"key":"331_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/09540261.2018.1482261","volume":"30","author":"S Ross","year":"2018","unstructured":"Ross, S. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int. Rev. Psychiatry 30, 317\u2013330 (2018).","journal-title":"Int. Rev. Psychiatry"},{"key":"331_CR22","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/npp.2017.84","volume":"42","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris, R. L. & Goodwin, G. M. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology 42, 2105\u20132113 (2017).","journal-title":"Neuropsychopharmacology"},{"key":"331_CR23","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross, S. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J. Psychopharmacol. 30, 1165\u20131180 (2016).","journal-title":"J. Psychopharmacol."},{"key":"331_CR24","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J. Psychopharmacol. 30, 1181\u20131197 (2016).","journal-title":"J. Psychopharmacol."},{"key":"331_CR25","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin, G. M. et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 387, 1637\u20131648 (2022).","journal-title":"N. Engl. J. Med."},{"key":"331_CR26","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison, C. L. et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 330, 843\u2013853 (2023).","journal-title":"JAMA"},{"key":"331_CR27","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. & Griffiths, R. R. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J. Psychopharmacol. 28, 983\u2013992 (2014).","journal-title":"J. Psychopharmacol."},{"key":"331_CR28","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz, M. P. et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 79, 953\u2013962 (2022).","journal-title":"JAMA Psychiatry"},{"key":"331_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/7854_2021_279","volume":"56","author":"K Ehrmann","year":"2022","unstructured":"Ehrmann, K., Allen, J. J. B. & Moreno, F. A. Psilocybin for the treatment of obsessive\u2013compulsive disorders. Curr. Top. Behav. Neurosci. 56, 247\u2013259 (2022).","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"331_CR30","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jpsychires.2023.03.031","volume":"161","author":"FR Schneier","year":"2023","unstructured":"Schneier, F. R. et al. Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder. J. Psychiatr. Res. 161, 364\u2013370 (2023).","journal-title":"J. Psychiatr. Res."},{"key":"331_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/02698811221140009","volume":"37","author":"N Ledwos","year":"2023","unstructured":"Ledwos, N., Rodas, J. D., Husain, M. I., Feusner, J. D. & Castle, D. J. Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder. J. Psychopharmacol. 37, 3\u201313 (2023).","journal-title":"J. Psychopharmacol."},{"key":"331_CR32","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1017\/S0033291700048017","volume":"13","author":"LR Derogatis","year":"1983","unstructured":"Derogatis, L. R. & Melisaratos, N. The Brief Symptom Inventory: an introductory report. Psychol. Med. 13, 595\u2013605 (1983).","journal-title":"Psychol. Med."},{"key":"331_CR33","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00213-022-06083-y","volume":"239","author":"A Sarparast","year":"2022","unstructured":"Sarparast, A., Thomas, K., Malcolm, B. & Stauffer, C. S. Drug\u2013drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 239, 1945\u20131976 (2022).","journal-title":"Psychopharmacology"},{"key":"331_CR34","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41593-022-01177-4","volume":"25","author":"AC Kwan","year":"2022","unstructured":"Kwan, A. C., Olson, D. E., Preller, K. H. & Roth, B. L. The neural basis of psychedelic action. Nat. Neurosci. 25, 1407\u20131419 (2022).","journal-title":"Nat. Neurosci."},{"key":"331_CR35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/0269881117725915","volume":"31","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris, R. L. & Nutt, D. J. Serotonin and brain function: a tale of two receptors. J. Psychopharmacol. 31, 1091\u20131120 (2017).","journal-title":"J. Psychopharmacol."},{"key":"331_CR36","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","volume":"21","author":"FX Vollenweider","year":"2020","unstructured":"Vollenweider, F. X. & Preller, K. H. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat. Rev. Neurosci. 21, 611\u2013624 (2020).","journal-title":"Nat. Rev. Neurosci."},{"key":"331_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/d41586-024-02154-6","volume":"632","author":"PD Petridis","year":"2024","unstructured":"Petridis, P. D. A psychedelic state arises from desynchronized brain activity. Nature 632, 32\u201333 (2024).","journal-title":"Nature"},{"key":"331_CR38","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1152\/jn.00338.2011","volume":"106","author":"BT Yeo","year":"2011","unstructured":"Yeo, B. T. et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J. Neurophysiol. 106, 1125\u20131165 (2011).","journal-title":"J. Neurophysiol."},{"key":"331_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41586-024-07624-5","volume":"632","author":"JS Siegel","year":"2024","unstructured":"Siegel, J. S. et al. Psilocybin desynchronizes the human brain. Nature 632, 131\u2013138 (2024).","journal-title":"Nature"},{"key":"331_CR40","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41583-021-00474-4","volume":"22","author":"J Smallwood","year":"2021","unstructured":"Smallwood, J. et al. The default mode network in cognition: a topographical perspective. Nat. Rev. Neurosci. 22, 503\u2013513 (2021).","journal-title":"Nat. Rev. Neurosci."},{"key":"331_CR41","doi-asserted-by":"publisher","first-page":"116287","DOI":"10.1016\/j.neuroimage.2019.116287","volume":"206","author":"HX Zhou","year":"2020","unstructured":"Zhou, H. X. et al. Rumination and the default mode network: meta-analysis of brain imaging studies and implications for depression. NeuroImage 206, 116287 (2020).","journal-title":"NeuroImage"},{"key":"331_CR42","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.euroneuro.2021.06.001","volume":"50","author":"MK Madsen","year":"2021","unstructured":"Madsen, M. K. et al. Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. Eur. Neuropsychopharmacol. 50, 121\u2013132 (2021).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"331_CR43","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","volume":"28","author":"RE Daws","year":"2022","unstructured":"Daws, R. E. et al. Increased global integration in the brain after psilocybin therapy for depression. Nat. Med. 28, 844\u2013851 (2022).","journal-title":"Nat. Med."},{"key":"331_CR44","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1126\/science.adf0435","volume":"379","author":"MV Vargas","year":"2023","unstructured":"Vargas, M. V. et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science 379, 700\u2013706 (2023).","journal-title":"Science"},{"key":"331_CR45","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","volume":"48","author":"AE Calder","year":"2023","unstructured":"Calder, A. E. & Hasler, G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology 48, 104\u2013112 (2023).","journal-title":"Neuropsychopharmacology"},{"key":"331_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881119897615","volume":"34","author":"GI Agin-Liebes","year":"2020","unstructured":"Agin-Liebes, G. I. et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J. Psychopharmacol. 34, 155\u2013166 (2020).","journal-title":"J. Psychopharmacol."},{"key":"331_CR47","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","volume":"36","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan, N. et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J. Psychopharmacol. 36, 151\u2013158 (2022).","journal-title":"J. Psychopharmacol."},{"key":"331_CR48","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","volume":"4","author":"DB Yaden","year":"2021","unstructured":"Yaden, D. B. & Griffiths, R. R. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol. Transl. Sci. 4, 568\u2013572 (2021).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"331_CR49","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1177\/0022167817706884","volume":"57","author":"AB Belser","year":"2017","unstructured":"Belser, A. B. et al. Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. J. Humanist. Psychol. 57, 354\u2013388 (2017).","journal-title":"J. Humanist. Psychol."},{"key":"331_CR50","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1177\/0022167817715966","volume":"57","author":"TC Swift","year":"2017","unstructured":"Swift, T. C. et al. Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. J. Humanist. Psychol. 57, 488\u2013519 (2017).","journal-title":"J. Humanist. Psychol."},{"key":"331_CR51","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1007\/s00213-022-06221-6","volume":"239","author":"M Butler","year":"2022","unstructured":"Butler, M., Jelen, L. & Rucker, J. Expectancy in placebo-controlled trials of psychedelics: if so, so what? Psychopharmacology 239, 3047\u20133055 (2022).","journal-title":"Psychopharmacology"},{"key":"331_CR52","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/jnci\/djp336","volume":"101","author":"A Vodermaier","year":"2009","unstructured":"Vodermaier, A., Linden, W. & Siu, C. Screening for emotional distress in cancer patients: a systematic review of assessment instruments. J. Natl Cancer Inst. 101, 1464\u20131488 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"331_CR53","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1002\/cncr.28750","volume":"120","author":"WF Pirl","year":"2014","unstructured":"Pirl, W. F. et al. Recommendations for the implementation of distress screening programs in cancer centers: report from the American Psychosocial Oncology Society (APOS), Association of Oncology Social Work (AOSW), and Oncology Nursing Society (ONS) joint task force. Cancer 120, 2946\u20132954 (2014).","journal-title":"Cancer"},{"key":"331_CR54","first-page":"65","volume":"6","author":"S Holm","year":"1979","unstructured":"Holm, S. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 6, 65\u201370 (1979).","journal-title":"Scand. J. Stat."}],"container-title":["Nature Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44220-024-00331-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44220-024-00331-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44220-024-00331-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T17:06:07Z","timestamp":1730912767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44220-024-00331-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":54,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["331"],"URL":"https:\/\/doi.org\/10.1038\/s44220-024-00331-0","relation":{},"ISSN":["2731-6076"],"issn-type":[{"value":"2731-6076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.J.Z. is a post-doctoral fellow in the NYU Langone Psychedelic Medicine Research Training program funded by MindMed. M.P.B. is principal investigator of the NYU Langone Center for Psychedelic Medicine Research Training Program, funded by MindMed. M.P.B. has received research funding from Tilray Canada, the Multidisciplinary Association for Psychedelic Studies (MAPS) PBC, B.More Inc., the Heffter Research Institute, the Turnbull Family Foundation, the Fournier Family Foundation, Dr. Bronner\u2019s Family Foundation, Bill Linton and the Riverstyx Foundation. M.P.B. serves on the Advisory Board of Ajna Labs LLC, Journey Colab and Bright Minds Biosciences, Inc. He is named as inventor on patent applications relating to the use of psilocybin for alcohol use disorder but has waived all rights and has no prospect of financial benefit. S.R. is the Director of NYU Langone Center for Psychedelic Medicine Research Training Program, which is funded by MindMed. S.R. currently receives, or has received in the past 36\u2009months, grant support for clinical research from the National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI), Heffter Research Institute, Usona Institute, Council on Spiritual Practices (CSP), Multidisciplinary Association of Psychedelic Studies (MAPS) and Reset Pharmaceuticals. S.R. is listed as a coinventor in two provisional patent applications (N420838US and N419987US) related to the use of psilocybin to treat psychiatric and existential distress in cancer. These provisional patent applications were filed by New York University Grossman School of Medicine and licensed by Reset Pharmaceuticals. S.R. has waived all rights in relation to these provisional patent applications and has no prospect of financial gain related to any future commercialization efforts related to these patents. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}